Alkermes
ALKS
44.94
-1.24
-2.69%
Alkermes
US · ALKS
#1780 by market cap
Listed 1970
44.94
-1.24
-2.69%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:01
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions decreased by 8 in the most recent period (2026/Q3).
- Total institutional ownership rose 0.7 percentage points.
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 109.98% +0.66pp
- Institutions
- 511 -8
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund72.41%
Hedge Fund25.58%
VC/PE Fund4.22%
Public Company2.86%
Government Pension Fund1.61%
Individual/Insider1.48%
Sovereign Wealth Fund1.29%
Private Company0.90%
Insurance Company0.73%
Top holders as of 2026-09-30
BlackRock
17.08% · 28.70M sh
State Street Global Advisors
6.03% · 10.13M sh
Baker Bros. Advisors LP
5.96% · 10.01M sh
Vanguard Portfolio Management, LLC
5.63% · 9.46M sh
T. Rowe Price Group, Inc.
4.66% · 7.83M sh
Vanguard Capital Management, LLC
4.47% · 7.50M sh
Renaissance Technologies Corp.
3.86% · 6.49M sh
Geode Capital Management, LLC
2.64% · 4.44M sh
Deep Track Capital, LP
2.38% · 4.00M sh
Dimensional Fund Advisors
2.50% · 4.19M sh
Holocene Advisors, LP
2.14% · 3.60M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 23 buys · 27 sells
| Name | Role | Stake |
|---|---|---|
| Richard Pops | Chairperson | 0.82% |
| Blair Jackson | Chief Executive Officer | 0.14% |
| David Gaffin | Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary | 0.13% |
| David Daglio | Former Independent Director | 0.06% |
| Shane Cooke | Independent Director | 0.06% |
| Christian Nichols | Chief Commercial Officer | 0.06% |
| Craig Hopkinson | Executive VP of Research & Development and Chief Medical Officer | 0.04% |
| Brian McKeon | Independent Director | 0.03% |
| Nancy Snyderman | Independent Director | 0.02% |
| Frank Wilson | Lead Independent Director | 0.02% |
| Richard Brian Gaynor | Independent Director | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-02 | David Gaffin | Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary | Automatic Disposition | -2,035 | $46.17 |
| 2026-10-07 | Joshua Reed | Senior Vice President | Derivative Exercise and Sale | -4,069 | $40.11 |
| 2026-10-07 | Joshua Reed | Senior Vice President | Derivative Exercise and Retained | +5,095 | -- |
| 2026-10-06 | Anne Michelle Whitaker | Independent Director | Other Derivative Acquisition | +7,239 | -- |
| 2026-10-06 | Anne Michelle Whitaker | Independent Director | Other Derivative Acquisition | +17,998 | $41.45 |
| 2026-10-01 | David Gaffin | Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary | Automatic Disposition | -2,034 | $41.03 |
| 2026-09-02 | David Gaffin | Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary | Automatic Disposition | -2,034 | $48.01 |
| 2026-08-31 | Craig Hopkinson | Executive VP of Research & Development and Chief Medical Officer | Automatic Disposition | -4,000 | $46.99 |
| 2026-08-31 | Craig Hopkinson | Executive VP of Research & Development and Chief Medical Officer | Derivative Exercise and Sale | -5,000 | $24.59–46.99 |
| 2026-08-16 | Christian Nichols | Chief Commercial Officer | Automatic Disposition | -7,576 | $49.19–49.65 |
| 2026-08-04 | Blair Jackson | Chief Executive Officer | Other Derivative Acquisition | +217,534 | $49.61 |
| 2026-08-02 | Nancy Snyderman | Independent Director | Derivative Exercise and Sale | -44,472 | $46.72–50.35 |
| 2026-08-02 | Craig Hopkinson | Executive VP of Research & Development and Chief Medical Officer | Automatic Disposition | -4,000 | $48.58 |
| 2026-08-02 | Craig Hopkinson | Executive VP of Research & Development and Chief Medical Officer | Derivative Exercise and Sale | -5,000 | $19.34–48.58 |
| 2026-08-02 | David Gaffin | Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary | Automatic Disposition | -2,034 | $48.58 |
| 2026-07-05 | David Gaffin | Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary | Automatic Disposition | -2,034 | $54.03 |
| 2026-06-30 | Craig Hopkinson | Executive VP of Research & Development and Chief Medical Officer | Automatic Disposition | -4,000 | $51.46–52.13 |
| 2026-06-30 | Craig Hopkinson | Executive VP of Research & Development and Chief Medical Officer | Derivative Exercise and Sale | -5,000 | $19.34–51.46 |
| 2026-06-11 | Christopher I. Wright | Independent Director | Automatic Disposition | -2,000 | $45.10 |
| 2026-06-03 | David Gaffin | Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary | Automatic Disposition | -2,034 | $43.05 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:01:09 · For reference only, not investment advice and not tailored to your situation.
Alkermes discussion 0 comments